From the Research
Tirzepatide (Mounjaro) is not available in tablet form at all, and it is only manufactured as a solution for subcutaneous injection in pre-filled, single-dose pens. The medication comes as a clear, colorless to slightly yellow solution that is ready to use without requiring reconstitution from either raw or lyophilized powder. The active ingredient tirzepatide is formulated in a liquid solution with excipients like sodium phosphate, sodium chloride, and water for injection 1. This injectable formulation is designed to deliver precise doses of the GLP-1/GIP receptor agonist for treatment of type 2 diabetes and weight management. The injectable route is necessary because tirzepatide is a peptide-based medication that would be broken down by digestive enzymes if taken orally, rendering it ineffective 2. Any claims about Mounjaro tablets would be referring to counterfeit products, as genuine tirzepatide is only available as an injectable medication. Key benefits of tirzepatide include its ability to lower A1C by 1.7-2.4% from baseline and achieve significant weight loss, with patients on tirzepatide 15 mg losing 8.8-12.9 kg (19.4-28.44 lb) or 9.17-13.7% body weight 3. Overall, tirzepatide is a potent new treatment option for type 2 diabetes and obesity, and its injectable formulation is a crucial aspect of its efficacy and safety profile 4.